Investor Presentaiton

Oncology: Solid performance across broad portfolio Lynparza olaparib tablets 150 mg • Lynparza¹ sales grew 6% driven primarily by pricing in the U.S. and increased demand in Latin America • Lenvima² sales grew 30% driven by timing of shipments in China and increased demand in advanced RCC and endometrial cancer indications in the U.S. $246M +25% Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai $284M +23% $299M +6% 3Q21 3Q22 3Q23 LENVIMA (lenvatinib) capsules and 10 mg 4 mg $188M +30% $202M $260M +30% +11% 3Q21 3Q22 3Q23 MERCK 12

View entire presentation